Results 181 to 190 of about 113,609 (263)

Emerging therapeutic advances for immune thrombocytopenia: highlights from selected early‑phase and pivotal trials at the 2025 ASH annual meeting. [PDF]

Exp Hematol Oncol
Cao L, Wang Z, Xiang Q.
europepmc   +1 more source

Clinical predictors of response to methotrexate in patients with rheumatoid arthritis: A systematic review

Rheumatology &Autoimmunity, EarlyView.
This review integrates clinical, immunological, genetic, and multi‐omic evidence, highlighting dynamic inflammatory and adenosine‐pathway biomarkers and reinforcing treat‐to‐target principles as the most actionable framework for personalized methotrexate therapy.
Joana Ramos Rodrigues, Helena Margarida de Miranda Lemos Romão Donato, Soraia Raquel Loureiro Azevedo, Luís Miguel da Silva Pires, Luís Pedro Bolotinha de Sousa Inês, Manuel Augusto Nunes Vicente Passos Morgado, Ana Filipa de Sousa Pestana Mourão   +6 more
wiley   +1 more source

CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study. [PDF]

HLA
Zheng H, Zhao H, Zhu X, Feng J, Wei G, Han S, Huang S, Cui J, Fu S, Zhang M, Zhang Y, Shi J, Luo Y, Chang AH, Hu Y, Huang H.   +15 more
europepmc   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Comparative efficacy and long-term survival of CD19/22 versus CD19 CAR-T immunotherapy in Relapsed/Refractory B-ALL with TP53 alterations. [PDF]

J Transl Med
Tang Y, Li M, Cui Q, Liu S, Li T, Qiu H, Kang L, Yu L, Wu D, Tang X.   +9 more
europepmc   +1 more source

immunoHuMiX: A personalizable gut‐on‐chip model for unraveling human microbiome–immune interactions

VIEW, EarlyView.
The study introduces a personalized gut model that brings together human immune cells and intestinal cells to better mimic how the body interacts with microbes. This system successfully maintained both human cells and a 17‐strain probiotic community, showing consistent immune responses across different donors.
Charlotte De Rudder, Kacy Greenhalgh, Joanna Baginska, Camille Martin‐Gallausiaux, Léa Grandmougin, Rémy Villette, Mara Lucchetti, Bérénice Hansen, Marek Ostaszewski, Viacheslav A. Petrov, Koji Atarashi, Lena Weidert, Audrey Frachet Bour, Dominik Ternes, Javier Ramiro‐Garcia, Antoine Malabirade, Takeshi Tanoue, Marc Mac Giolla Eain, Elisabeth Letellier, Matthew Barrett, Jérôme Lacombe, Frederic Zenhausern, Coralie Guérin, Markus Ollert, Carole Seguin‐Devaux, Kenya Honda, Paul Wilmes   +26 more
wiley   +1 more source

CAR-T cell therapy for autoimmune diseases: current clinical trial landscape and the next wave of development. [PDF]

Front Immunol
Chen Q, Zhu Y, Xu Q, He Y, Wang Y, Wang Z, Dong W.   +6 more
europepmc   +1 more source

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

CD21⁺CD11c⁺ B cells predicting handgrip strength decline in older adults. [PDF]

Front Aging
Mabe-Castro D, Mabe-Castro M, Varón LS, Navarrete MA, Castillo-Aguilar M, Núñez-Espinosa C.   +5 more
europepmc   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source